Dr. Sharma Discusses Updates from CheckMate-275 in Bladder Cancer

Padmanee Sharma, MD, PhD, scientific director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, discusses updated findings from the CheckMate-275 trial in bladder cancer during an interview at the 2018 AACR Annual Meeting.

Results from the CheckMate-275 trial previously confirmed the efficacy and safety of nivolumab (Opdivo) monotherapy in this population. Updated data showed that, at a median follow-up of 24.5 months, the overall response rate was 20.4% for all treated patients. In addition to the previously reported 17 complete responses (CRs), this update showed 9 more CRs.

Sharma says that immunotherapy should be considered as one of the primary pillars in treating patients with metastatic bladder cancer. She adds that there is a lot of information available on how to administer and manage patients on immunotherapies for the community oncologist.